Evalueserve

DECEMBER 6, 2021

Global Healthcare Market – 2021. However, the emergence of a Delta variant of COVID-19 in Europe, the US, and China is fueling the need for ‘booster shots’ to sustain global recovery. According to the IMF, the global economy is likely to grow by 5.9% Global Healthcare M&A: Unprecedented Fightback 2.0.

Capital 98

Capital Globalization Biotech Marketing 98

Sedulo

MARCH 15, 2023

Our analysis of global data gathered from multiple trial registries provided a compelling snapshot of the recent IO clinical landscape and prompted several unanswered questions regarding future evolution and the impact on manufacturers competing in the space. Monitor key activity within the landscape.

Biotech 52

Biotech Competitive Landscape Pharmaceutical Benchmarking 52

Alpha Sense BI

MAY 5, 2023

After three volatile years, rife with challenging macroeconomic conditions — from a global pandemic and wars to far-reaching supply chain issues — the M&A space has its fair share of ups and downs. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 29, 2024

Market Analysis : A valuable tool for conducting market research , as it can analyze large volumes of market data, predict market trends, analyze customer preferences, and provide a snapshot of the competitive landscape. Forecasting Analysis : Analyze financial data to generate potential forecasts.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. As we navigate 2024, the landscape appears positioned for a triumphant comeback. In fact, projections for the global spatial computing market are valued at $269.8 billion by 2030 with a CAGR of 23.1%

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

MARCH 28, 2023

Value: To date, GLG serves leading technology, life science, and industrial companies, including 40% of the Fortune 100 and seven of the top 10 global technology companies; leading investment and financial firms; top professional services firms; and hundreds of nonprofits and social entrepreneurs around the world.

Value Chain 52

Value Chain Biotech Research Pharmaceutical 52